<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        142-186-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AMCOCID 100MG-2ML INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMIKACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        66.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01GB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Amcocid</strong> contains amikacin sulphate<strong> </strong>as the active ingredient.</p><p>Amikacin is an antibiotic and belongs to the group of medicines called aminoglycosides.</p><p><strong>Amcocid</strong> is used to treat serious infections caused by certain bacteria.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Amcocid if:</strong></p><p>&bull;&nbsp; <strong>&nbsp;</strong>You are allergic (hypersensitive) to any of the ingredients in <strong>Amcocid</strong> or other antibiotics.</p><p>&bull;&nbsp; You suffer from myasthenia gravis (a disease that causes muscle weakness).</p><p>If any of the above affects you, or you are unsure if they do, tell your doctor who will be able to advise you.</p><p><strong>You must tell your doctor if:&nbsp; </strong></p><p>&bull;&nbsp; You have any kidney problems</p><p>&bull;&nbsp; You have any hearing problems or other problems with your ears.</p><p>&bull;&nbsp; You have any muscular disorders such as Parkinson&#39;s Disease</p><p>Take caution if you are elderly</p><p><strong>Take caution if you are dehydrated (ensure you are well hydrated during treatment) </strong></p><p><strong>Other medicines and Amcocid</strong></p><p>Always tell your doctor or pharmacist about any other medicines you may be taking or have recently taken including those obtained without a prescription before you are given <strong>Amcocid</strong>. Some medicines can have an effect on the action of other medicines. It is especially important that you tell your doctor if you are taking;</p><p>&bull;&nbsp; Any diuretics e.g. frusemide (water tablet or injection)</p><p>&bull;&nbsp; Any antibiotics including, penicillin-type antibiotics or cephalosporins</p><p>&bull;&nbsp; Any muscle relaxing medication</p><p>&bull;&nbsp; Cisplatin use in the treatment of cancers</p><p>&bull;&nbsp; Amphotericin B, which is used in the treatment of fungal infections</p><p>&bull;&nbsp; Bisphosphonates (which are used to treat osteoporosis and similar diseases)</p><p>&bull;&nbsp; Platinum compounds</p><p>&bull;&nbsp; Thiamine (Vitamin B<sub>1</sub>) as it may lose its effectiveness</p><p>&bull;&nbsp; Any other medicines which are bad for your kidneys or hearing</p><p>&bull;&nbsp; Indomethacin (an anti-inflammatory). This can increase the amount of amikacin which is absorbed in new born babies</p><p>Or</p><p>&bull;&nbsp; If you have recently received an anaesthetic.</p><p><strong>Amcocid</strong> is not recommended to be given by injection into the stomach in young children.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, or think you may be pregnant, you should speak to your doctor before you are given <strong>Amcocid</strong>.</p><p><strong>Driving and using machines</strong></p><p>If you feel unwell or suffer from any of the side effects do not drive or operate machinery.</p><p><strong>Important information about some ingredients of Amcocid</strong></p><p><strong>Amcocid</strong> injection contains the inactive ingredient sodium metabisulphite which may rarely cause severe hypersensitivity reactions and bronchospasm (difficulty in breathing or wheezing).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Amcocid</strong> is usually given by a doctor or nurse.<strong> Amcocid</strong> is given by injection into a muscle or vein, or occasionally into the abdomen. The patient&#39;s pre-treatment body weight should be obtained in order to calculate the correct dosage. The usual duration of the treatment is 7 to 10 days. The total daily dose by all routes of administration should not exceed 15-20 mg/kg/day.</p><p><strong>Adults and children over 12 years: </strong>The usual dose is 15 mg/kg/day which is given once a day or divided into two doses which are given twice a day.</p><p><strong>Elderly: </strong>Renal function should be assessed and dose adjusted as described under impaired renal function.</p><p><strong>Children aged 4 weeks to 12 years: </strong>The usual dose is 15 &ndash; 20 mg/kg/day which is given once a day or divided into two doses which are given twice a day.</p><p><strong>Neonates: </strong>The usual dose is initially 10 mg/kg followed by 7.5 mg/kg which is given twice a day.</p><p><strong>Premature infants: </strong>The usual dose is 7.5 mg/kg twice a day.</p><p><strong>Life-threatening infection and/or those caused by Pseudomonas: </strong>The doses may be increased to 500 mg every eight hours, but should not exceed 1.5 g/day or be administered for a period longer than 10 days.</p><p><strong>Urinary tract infections: </strong>The usual dose is 7.5 mg/kg/day twice a day.</p><p><strong>Impaired renal function: </strong>The daily dose should be reduced and/or the interval between doses increased to avoid buildup of drug.</p><p>The doses may be increased in certain infections.</p><p>You may require hearing and kidney tests while receiving <strong>Amcocid</strong> as well as blood tests to check the amount of amikacin received.</p><p>You should start to see an improvement in 1-2 days. If there has been no improvement after 3-5 days, go back to see your doctor.</p><p><strong>If you are given too much or too little Amcocid Injection&nbsp; </strong></p><p><strong>Amcocid</strong> will be given by a qualified healthcare professional (doctor or nurse) who will ensure you are given the correct dose. On rare occasions, you may be given too much <strong>Amcocid</strong>. If this happens, your doctor will make sure that it is removed from your blood so that you do not suffer too many side effects.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, <strong>Amcocid</strong> can cause unwanted side effects, although not everybody gets them.</p><p>If you notice any of the following, stop taking <strong>Amcocid</strong> and contact your doctor immediately:</p><p>&bull;&nbsp; swelling of the face, lips, or tongue</p><p>&bull;&nbsp; skin rash</p><p>&bull;&nbsp; difficulty breathing</p><p>As these may be signs of an allergic reaction</p><p><strong>The frequency of possible side effects listed below is defined using the following convention:&nbsp;&nbsp;&nbsp; </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>very common:</p></td><td style="vertical-align:top"><p>affects more than 1 user in 10</p></td></tr><tr><td style="vertical-align:top"><p>common:</p></td><td style="vertical-align:top"><p>affects 1 to less than 10 users in 100</p></td></tr><tr><td style="vertical-align:top"><p>uncommon:</p></td><td style="vertical-align:top"><p>affects 1 to less than 10 users in 1,000</p></td></tr><tr><td style="vertical-align:top"><p>rare:</p></td><td style="vertical-align:top"><p>affects 1 to less than 10 users in 10,000</p></td></tr><tr><td style="vertical-align:top"><p>very rare:</p></td><td style="vertical-align:top"><p>affects less than 1 user in 10,000</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Patients treated with amikacin have reported the following side effects:</p><p><strong><u>Uncommon</u></strong></p><p>&bull;&nbsp; feeling sick (nausea) and being sick (vomiting)</p><p>&bull;&nbsp; skin rash</p><p>&bull;&nbsp; infections with resistant bacteria or yeasts</p><p><strong><u>Rare</u></strong></p><p>&bull;&nbsp; abnormal white blood cells, which can be detected by blood tests</p><p>&bull;&nbsp; reduced magnesium levels in the blood</p><p>&bull;&nbsp; headache</p><p>&bull;&nbsp; tremor</p><p>&bull;&nbsp; muscle twitching</p><p>&bull;&nbsp; pins and needles</p><p>&bull;&nbsp; numbness</p><p>&bull;&nbsp; blindness or other problems with your vision</p><p>&bull;&nbsp; low blood pressure</p><p>&bull;&nbsp; ringing in the ears</p><p>&bull;&nbsp; loss of hearing</p><p>&bull;&nbsp; joint pain</p><p>&bull;&nbsp; itching and hives</p><p>&bull;&nbsp; kidney problems including a reduction in urine output and increased nitrogen in the urine</p><p>&bull;&nbsp; fever</p><p>&bull;&nbsp; dizziness</p><p>&bull;&nbsp; anaemia (reduction in red blood cells which can make the skin pale and cause weakness or breathlessness)</p><p><strong>Other side effects where the frequencies are unknown include: </strong></p><p>&bull;&nbsp; inability of muscles to move</p><p>&bull;&nbsp; wheezing, difficulty breathing</p><p>&bull;&nbsp; temporarily stopping breathing</p><p>&bull;&nbsp; deafness</p><p><strong>If any of the side effects gets worse, or if you notice any side effects not listed in this leaflet, please tell your doctor.</strong></p><p><strong><u>To report any side effect(s):</u></strong><strong><u> </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222,</p><p><strong>Exts:</strong> 2317-2356-2340</p><p><strong>Reporting Hotline:</strong> 19999</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc<strong>.</strong></p><p><strong>By reporting side affects you can help provide more information on the safety of this medicine.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Amcocid </strong>after the expiry date which is stated on the carton and on the ampoule.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <em>Store below 30<sup>o</sup>C.</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Do not use <strong>Amcocid </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is amikacin. Each ampoule (2mL) of <strong>Amcocid</strong> contains amikacin sulphate equivalent to 100mg or 500mg amikacin.</p><p>The other ingredients: Sodium metabisulphite and sodium citrate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amcocid solution for injection is available in packs contain 5 or 50 ampoules (each ampoule contains 100mg or 500mg of amikacin per 2mL).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot;Julphar&quot;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/03/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>على المادة الفعالة كبريتات الأميكاسين.</p><p dir="RTL"><strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>&nbsp;هو مضاد حيوي ينتمي إلى مجموعة من الأدوية التي تعرف باسم أمينوجليكوسيدات.</p><p dir="RTL">يستخدم <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>&nbsp;في علاج العدوى الخطيرة الناجمة عن أنواع معينة من البكتيريا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطائك أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;في الحالات التالية: </strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من الحساسية تجاه أياً من المكونات في <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;&nbsp;</strong>أو تجاه المضادات الحيوية الأخرى</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من الوهن العضلي الوبيل (هي حالة مرضية تسبب ضعف في العضلات)</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج فهو الشخص الذي بإمكانه تقديم النصحية لك، إذا كان أي مما ذكر أعلاه ينطبق عليك، أو في حال لم تكن متأكداً من ذلك.</p><p dir="RTL"><strong>يجب عليك إخبار طبيبك المعالج </strong>إذا كنت تعاني من<strong>:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية مشاكل في الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية مشاكل في السمع أو مشاكل أخرى في الاذن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية اضطرابات في العضل على سبيل المثال مرض باركنسون &nbsp;</p><p dir="RTL"><strong>يجب عليك توخي الحذر إذا كنت من فئة كبار السن</strong></p><p dir="RTL"><strong>يجب عليك توخي الحذر إذا كنت تعاني من الجفاف (يجب أن تحرص على شرب السوائل بشكلٍ كافٍ أثناء فترة العلاج)</strong></p><p dir="RTL"><strong>تناول الأدوية الأخرى مع أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong></p><p dir="RTL">يجب عليك دائماً إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه حول أية أدوية أخرى التي قد تتناولها أو تناولتها مؤخراً بما في ذلك الأدوية التي تصرف دون وصفة طبية قبل إعطائك <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>. من الممكن أن تؤثر بعض الأدوية على آلية عمل الأدوية الأخرى. من المهم إخبار طبيبك المعالج وبصفة خاصة إذا كنت تتناول أحد الأدوية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية مدرات البول على سبيل المثال &nbsp;فوروسيميد (قرص أو حقنة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية مضادات حيوية بما في ذلك بنسيلين وهو أحدى أنواع المضادات الحيوية أو السيفالوسبورين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية أدوية تعمل على استرخاء العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; سيسبلاتين &nbsp;الذي يستخدم في علاج السرطان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الأمفوتريسين بي، الذي يستخدم في علاج الالتهابات الفطرية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; البايفوسفونيت (تسخدم لعلاج أمراض هشاشة العظام والحالات المرضية المشابهة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; مركبات البلاتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الثيامين (فيتامين ب<sub>1</sub>) لأنها قد تفقد فعاليتها</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أية أدوية أخرى والتي لها تأثير سيء على &nbsp;الكلى أو السمع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; اندوميثاسين (مضاد للالتهابات). من الممكن أن يزيد هذا الدواء من معدل امتصاص أميكاسين لدى الأطفال حديثي الولادة</p><p dir="RTL">أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; إذا تلقيت مؤخراً دواءً مخدراً</p><p dir="RTL">لا يوصى بإعطاء <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>عن طريق الحقن في المعدة للأطفال.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، أو تعتقدين أنك حاملاً، فيرجى منك إخبار طبيبك المعالج قبل إعطائك <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>.</p><p dir="RTL"><strong>القيادة واستخدام الألات</strong></p><p dir="RTL">يرجى منك عدم القيادة أو تشغيل الالات إذا شعرت بالتوعك أو المعاناة من أية تأثيرات الجانبية.</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong></p><p dir="RTL">يحتوي <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>على ميتا ثنائي كبريتيت الصوديوم الذي قد يسبب بصورة نادرة تفاعلات فرط الحساسية الشديدة وتشنج قصبي (صعوبة في التنفس أو أزيز)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة مايتم إعطاء <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>بواسطة الطبيب المعالج أو الممرض.<strong> </strong>يتم إعطاء <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>عن طريق الحقن في العضل أو الوريد، أو في بعض الأحيان في منطقة البطن. قبل بدء العلاج يجب معرفة وزن جسم المريض لحساب مقدار الجرعة الصحيحة له. تبلغ مدة العلاج الاعتيادية من &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 إلى 10 أيام. يجب أن لا يتجاوز مقدار الجرعة الكلية عن 15-20 ملغم/كغم/ يومياً لجميع طرق إعطاء هذا الدواء.</p><p dir="RTL"><strong>البالغون والأطفال بعمر أكبر من 12: </strong>يبلغ مقدار الجرعة الاعتيادية 15 ملغم/كغم/يومياً ويتم إعطائها مرة واحدة في اليوم أو تقسم إلى جرعتين متساويتين ويتم إعطائها مرتين في اليوم.</p><p dir="RTL"><strong>الأطفال بعمر 4 أسابيع إلى 12 سنة: </strong>يبلغ مقدار الجرعة الاعتيادية 15-20 ملغم/كغم يومياً ويتم إعطائها مرة واحدة في اليوم. وتقسم إلى جرعتين متساويتين ويتم إعطائها مرتين في اليوم.</p><p dir="RTL"><strong>الأطفال </strong><strong>حديثي</strong><strong> </strong><strong>الولادة: </strong>يبلغ مقدار الجرعة الابتدائية 10 ملغم/كغم وتليها جرعة بمقدار 7,5 ملغم/كغم ويتم إعطائها مرتين في اليوم.</p><p dir="RTL"><strong>الأطفال الخدج:</strong> يبلغ مقدار الجرعة الابتدائية 7,5 ملغم/كغم مرتين في اليوم.</p><p dir="RTL"><strong>عدوى&nbsp; طويلة المدى و/أو العدوى الناجمة من&nbsp; السودوموناس: </strong>قد تزداد مقدار الجرعة إلى 500 ملغم كل 8 ساعات، ولكن يجب أن لا تتجاوز 1,5 غرام/يومياً أو ويجب إعطائها لفترة زمنية لا تزيد عن 10 أيام.</p><p dir="RTL"><strong>عدوى الجهاز البولي: </strong>يبلغ مقدار الجرعة الاعتيادية 7,5 ملغم/كغم/ يومياً مرتين في اليوم.</p><p dir="RTL"><strong>اضطرابات في وظائف الكلى: </strong>يجب أن يتم تخفيض الجرعة اليومية و/أو زيادة&nbsp; المدة الفاصلة بين الجرعات لتجنب تراكم الدواء.</p><p dir="RTL">قد يزداد مقدار الجرعة لحالات معينة من العدوى.</p><p dir="RTL">قد يتطلب منك إجراء فحوصات للسمع والكلى قبل أن يتم إعطائك <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>&nbsp;أيضاً بإجراء فحوصات للدم للتأكد من مقدار أميكاسين في الدم.</p><p dir="RTL">من المفترض أن تتحسن حالتك الصحية في غضون 1-2 يوم. في حال عدم تحسن حالتك الصحية بعد مرور 3-5 أيام، يرجى منك رؤية طبيبك المعالج.</p><p dir="RTL"><strong>إذا تم إعطائك </strong><strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;بجرعة أكبر</strong><strong> </strong><strong>أو أقل مما يجب</strong></p><p dir="RTL">سوف يتم إعطاؤك <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>بواسطة طاقم طبي مؤهل لذلك (الطبيب المعالج أو الممرض) الذي سوف يحرص على إعطاؤك الجرعة الصحيحة من الدواء الخاص بك. في حالات نادرة، قد يتم إعطاؤك <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>بجرعة أكبر مما يجب. في حال حدوث ذلك، سوف يحرص طبيبك المعالج على التخلص من الكمية الزائدة من الدواء في الدم لديك لكي لا تعاني من العديد من التأثيرات الجانبية.</p><p dir="RTL"><strong>إذا كان لديك أي أسئلة أخرى فيما يخص استعمال هذا الدواء، يرجى استشارة طبيبك المعالج، الممرضة أو الصيدلي الذي تتعامل معه.</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، قد يؤدي <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>إلى حدوث تأثيرات جانبية غير مرغوب بها، ولكنها لا تحدث لكل شخص.</p><p dir="RTL">يرجى منك التوقف عن أخذ <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>والتواصل مع طبيبك المعالج على الفور، إذا لاحظت حدوث أياً مما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تورم الوجه، الشفتين، اللسان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">قد تكون تلك علامات لحدوث تفاعل تحسسي</p><p dir="RTL"><strong>تم تقدير معدل تكرار حدوث التأثيرات الجانبية المذكورة أدناه على النحو التالي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>شائعة جداً:</strong></p></td><td style="vertical-align:top"><p dir="RTL">تؤثر على أكثر من شخص واحد من كل 10 أشخاص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>شائعة:</strong></p></td><td style="vertical-align:top"><p dir="RTL">تؤثر على شخص واحد إلى أقل من عشرة من كل 100 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>غير شائعة:</strong></p></td><td style="vertical-align:top"><p dir="RTL">تؤثر على شخص واحد إلى أقل من عشرة من كل 1000 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>نادرة:</strong></p></td><td style="vertical-align:top"><p dir="RTL">تؤثر على شخص واحد إلى أقل من عشرة من كل 10000 شخص</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>نادرة جداً:</strong></p></td><td style="vertical-align:top"><p dir="RTL">تؤثر على أقل من شخص واحد من كل 10000 شخص</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">لقد تم تسجيل حدوث التاُثيرات الجانبية التالية لدى المرضى الذين تم إعطائهم أميكاسين:</p><p dir="RTL"><strong><u>غير شائعة</u></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (غثيان) والتوعك (تقيؤ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المصاحبة بالبكتيريا المقاومة أو الخمائر</p><p dir="RTL"><strong><u>النادرة</u></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في خلايا الدم البيضاء، الذي من الممكن اكتشافه عن طريق إجراء فحوصات الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات المغنسيوم في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوخز كوخز الدبابيس والابر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; تخدر وتنميل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر أو مشاكل أخرى في الرؤية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي على شكل خلايا النحل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى بما في ذلك قلة التبول وزيادة النيتروجين في البول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض خلايا الدم الحمراء الأمر الذي يجعل الجلد شاحب اللون ويسبب الضعف وضيق في التنفس)</p><p dir="RTL"><strong>تتضمن التأثيرات الجانبية الأخرى ولكن معدل تكرارها غير معروف على:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على تحريك العضلات &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; أزيز، صعوبة في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; توقف التنفس بشكل مؤقت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; فقدان السمع</p><p dir="RTL"><strong>في </strong><strong>حال زيادة حدة التأثيرات الجانبية،</strong><strong> أو إذا لاحظت حدوث تأثيرات جانبية أخرى لم تذكر في هذه النشرة، يرجى منك إخبار طبيبك المعالج.</strong></p><p dir="RTL"><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية</u></strong><strong><u>:</u></strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL"><strong>رقم الفاكس:&nbsp; </strong>&nbsp;7662-205-11-966+</p><p dir="RTL"><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على:</strong> 2038222-11-966+، <strong>وصلة هاتف:</strong>2340-2356-2317</p><p dir="RTL"><strong>الخط الساخن: </strong>19999</p><p dir="RTL"><strong>البريد الإلكتروني:</strong><strong> </strong><strong>&nbsp;</strong>npc.drug@sfda.gov.sa</p><p dir="RTL"><strong>الموقع الإلكتروني: </strong>www.sfda.gov.sa/npc</p><p dir="RTL"><strong>إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عدم استعمال <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>بعد تاريخ انتهاء الصلاحية المذكور على العبوة والأمبولة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&deg;م.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عدم استعمال <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أميكاسين. تحتوي كل أمبولة من <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong>&nbsp;(2 ملليلتر) على كبريتات الأميكاسين بما يعادل 100 ملغم أو 500 ملغم أميكاسين.</p><p dir="RTL">المواد الاخرى: ميتا ثنائي كبريتيت الصوديوم وسترات الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر محلول <strong>أمكوسي</strong><strong>ـ</strong><strong>د</strong><strong> </strong><strong>&nbsp;</strong>للحقن في عبوات تحتوي على 5 أو 50 أمبولة (تحتوي كل أمبولة على 100 ملغم أو 500 ملغم من الأميكاسين لكل</p><p dir="RTL">&nbsp;2 ملليلتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الخليج للصناعات الدوائية &quot;جلفار&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            4/3/2019م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amcocid 100mg/2mL Solution for I.M. / I.V. Injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ampoule (2mL) contains:
Item No.	Material Name 	Scale (mg/2mL)
		
	Active Ingredient:	
1.		Amikacin (use: Amikacin Sulphate)	100.00
		
	Inactive Ingredients:	
1.		Sodium metabisulphite 	2.60
2.		Sodium citrate dihydrate 	10.00
3.		Sodium hydroxide pellets 	q.s. 
4.		Sulphuric acid reagent grade 	q.s. 
5.		Nitrogen gas 	q.s. 
6.		Water for injection	q.s. to 2mL

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for I.M. / I.V. Injection
Description: Clear, colourless to light straw coloured solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amikacin sulphate is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including&nbsp;<em>Pseudomonas</em>&nbsp;spp,&nbsp;<em>Escherichia coli</em>, indole-positive and indole-negative&nbsp;<em>Proteus</em>&nbsp;spp,&nbsp;<em>Klebsiella-Enterobacter-Serratia</em>&nbsp;spp,&nbsp;<em>Salmonella, Shigella</em>,&nbsp;<em>Minea-Herellae, Citrobacter freundii</em>&nbsp;and&nbsp;<em>Providencia</em>&nbsp;spp.</p><p>Many strains of these gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin&nbsp;<em>in vitro</em>. The principal Gram-positive organism sensitive to amikacin is&nbsp;<em>Staphylococcus aureus</em>, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of&nbsp;<em>Streptococcus</em>&nbsp;<em>pyogenes</em>, Enterococci and&nbsp;<em>Diplococcus pneumoniae</em>.</p><p><strong>Amcocid</strong> is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. It may also be indicated for the treatment of known or suspected staphylococcal disease.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For most infections the intramuscular route is preferred, but in life-threatening infections, or in patients in whom intramuscular injection is not feasible the intravenous route, either slow bolus (2 to 3 minutes) or infusion (0.25% over 30 minutes) may be used.</p><p><strong><u>Intramuscular and intravenous administration</u></strong></p><p>Amikacin sulphate injection may be given intramuscularly or intravenously.</p><p>At the recommended dosage level, uncomplicated infections due to sensitive organisms should respond to therapy within 24 to 48 hours.</p><p>If clinical response does not occur within three to five days consideration should be given to alternative therapy.</p><p>The patient&#39;s pre-treatment body weight should be obtained for calculation of correct dosage.</p><p>The status of renal function should be estimated by measurement of the serum creatinine concentration or calculation of the endogenous creatinine clearance rate. The blood urea nitrogen (BUN) is much less reliable for this purpose. Reassessment of renal function should be made periodically during therapy.</p><p>Whenever possible, amikacin concentrations in serum should be measured to assure adequate, but not excessive levels. It is desirable to measure both peak and trough serum concentrations intermittently during therapy. Peak concentrations (30-90 minutes after injection) above 35 mcg/mL and trough concentrations (just prior to the next dose) above 10 mcg/mL should be avoided. Dosage should be adjusted as indicated. In patients with normal renal function, once daily dosing may be used; peak concentrations in these cases may exceed 35 mcg/mL.</p><p>The usual duration of treatment is 7 to 10 days. The total daily dose by all routes of administration should not exceed 15-20 mg/kg/day. In difficult and complicated infections where treatment beyond 10 days is considered, the use of amikacin sulphate injection should be re-evaluated and if continued, renal, auditory, vestibular function should be monitored, as well as serum amikacin levels.</p><p>If definite clinical response does not occur within 3 to 5 days, therapy should be stopped and the antibiotic susceptibility pattern of the invading organism should be rechecked. Failure of the infection to respond may be due to resistance of the organism or to the presence of septic foci requiring surgical drainage.</p><p><strong>Adults and children over 12 years:&nbsp;</strong>The recommended intramuscular or intravenous dosage for adults and adolescents with normal renal function (creatinine clearance &ge;50 mL/min) is 15 mg/kg/day which may be administered as a single daily dose or divided into 2 equal doses i.e. 7.5 mg/kg every 12 hours. The total daily dose should not exceed 1.5 g. In endocarditis and in febrile neutropenic patients dosing should be twice daily, as there is not enough data to support once daily dosing.</p><p><strong>Children 4 weeks to 12 years:&nbsp;</strong>The recommended intramuscular or intravenous (slow intravenous infusion) dose in children with normal renal function is 15-20 mg/kg/day which may be administered as 15-20 mg/kg, once a day; or as 7.5 mg/kg every 12 hours. In endocarditis and in febrile neutropenic patients dosing should be twice daily, as there is not enough data to support once daily dosing.</p><p><strong>Neonates:&nbsp;</strong>An initial loading dose of 10 mg/kg followed by 7.5 mg/kg every 12 hours (see sections 4.4 and 5.2).</p><p><strong>Premature infants</strong>: The recommended dose in prematures is 7.5 mg/kg in every 12 hours (see sections 4.4 and 5.2).</p><p><strong>Specific recommendation for intravenous administration</strong></p><p>The solution for intravenous use is prepared by adding the desired dose to 100mL or 200mL of sterile diluent such as normal saline or 5% dextrose in water or any other compatible solution. The solution is administered to adults over a 30 to 60 minute period.</p><p>In paediatric patients the amount of diluents used will depend on the amount of amikacin tolerated by the patient. The solution should normally be infused over a 30 to 60 minute period. Infants should receive a 1 to 2 hour infusion.</p><p>Amikacin should not be physically premixed with other drugs, but should be administered separately according to the recommended dose and route.</p><p><strong><u>Elderly</u></strong></p><p>Amikacin is excreted by the renal route. Renal function should be assessed whenever possible and dosage adjusted as described under impaired renal function.</p><p><strong><u>Life-threatening infections and/or those caused by Pseudomonas</u></strong></p><p>The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 15 g should not be exceeded.</p><p><strong><u>Urinary tract infections (other than pseudomonal infections):</u></strong></p><p>7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg twice daily in adults). As the activity of amikacin is enhanced by increasing the pH, a urinary alkalising agent may be administered concurrently.</p><p><strong><u>Impaired renal function</u></strong></p><p>In patients with renal impairment reflected by creatinine clearance less than 50 mL/min, administration of the recommended total daily dose of amikacin in single daily doses is not desirable since these patients will have protracted exposure to high trough concentrations. See below for dosage adjustments in patients with impaired renal function.</p><p>For patients with impaired renal function receiving usual twice or three times daily dosing, whenever possible, serum amikacin concentrations should be monitored by appropriate assay procedures. Doses should be adjusted in patients with impaired renal function either by administering normal doses at prolonged intervals or by administering reduced doses at fixed intervals.</p><p>Both methods are based on the patient&#39;s creatinine clearance or serum creatinine values since these have been found to correlate with aminoglycoside half-lives in patients with diminished renal function. These dosage schedules must be used in conjunction with careful clinical and laboratory observations of the patient and should be modified as necessary, including modification when dialysis is being performed.</p><p><em>Normal Dose at Prolonged Intervals Between Dosing:&nbsp;</em>If the creatinine clearance rate is not available and the patient&#39;s condition is stable, a dosage interval in hours for the normal single dose (i.e., that which would be given to patients with normal renal function on a twice daily schedule, 7.5 mg/kg) can be calculated by multiplying the patient&#39;s serum creatinine concentration (in mg/100mL) by nine; e.g. if the serum creatinine concentration is 2 mg/100 mL, the recommended single dose (7.5 mg/kg) should be administered every 18 hours.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~22773~6~142223A.PNG"
 style='position:absolute;left:0;text-align:left;margin-left:81.95pt;
 margin-top:7.2pt;width:236.1pt;height:213.5pt;z-index:251657728;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:\Users\bayan\AppData\Local\Temp\msohtmlclip1\01\clip_image001.png"
  o:href="https://www.medicines.org.uk/emc/images/spc/spc~22773~6~142223A.PNG"/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="315" height="285" alt="https://www.medicines.org.uk/emc/images/spc/spc~22773~6~142223A.PNG" src="file:///C:\Users\bayan\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Reduced Dose at Fixed Time Intervals between Dosing:&nbsp;</em>When renal function is impaired and it is desirable to administer amikacin sulphate injection at a fixed time interval, dose must be reduced. In these patients, serum amikacin concentrations should be measured to assure accurate administration and to avoid excessive serum concentrations. If serum assay determinations are not available, and the patient&#39;s condition is stable, serum creatinine and creatinine clearance values are the most readily available indicators of the degree of renal impairment to use as a guide for dosage.</p><p>First, initiate therapy by administering a normal dose, 7.5 mg/kg, as a loading dose. This dose is the same as the normally recommended dose which would be calculated for a patient with a normal renal function as described above.</p><p>To determine the size of maintenance doses administered every 12 hours, the loading dose should be reduced in proportion to the reduction in the patient&#39;s creatinine clearance rate:</p><p>Maintenance dose every 12 hours =</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" alt="spc~22773~6~142223B"
 style='width:303.75pt;height:38.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:\Users\bayan\AppData\Local\Temp\msohtmlclip1\01\clip_image003.png"
  o:title="spc~22773~6~142223B"/>
</v:shape><![endif]--><img width="405" height="51" alt="spc~22773~6~142223B" src="file:///C:\Users\bayan\AppData\Local\Temp\msohtmlclip1\01\clip_image004.gif" /></p><p>(CrCl = creatinine clearance rate)</p><p>An alternate rough guide for determining reduced dosage at twelve-hour intervals (for patients whose steady state serum creatinine values are known) is to divide the normally recommended dose by the patient&#39;s serum creatinine.</p><p>The above dosage schedules are not intended to be rigid recommendations, but are provided as guides to dosage when the measurement of amikacin serum levels is not feasible.</p><p>As renal function may alter appreciably during therapy, the serum creatinine should be checked frequently and the dosage regimen modified as necessary.</p><p><strong><u>Intraperitoneal use</u></strong></p><p>The intraperitoneal use of amikacin is not recommended in young children.</p><p>Following exploration for established peritonitis, or after peritoneal contamination due to faecal spill during surgery, Amikacin may be used as an irrigant after recovery from anaesthesia in concentrations of 0.25% (2.5 mg/mL). If instillation is desired in adults, a single dose of 500 mg is diluted in 20 mL of sterile distilled water and may be instilled through a polyethylene catheter sutured into the wound at closure. If possible, instillation should be postponed until the patient has fully recovered from the effects of anaesthesia and muscle-relaxing drugs.</p><p><strong><u>Other routes of administration</u></strong></p><p>Amikacin in concentrations of 0.25% (2.5 mg/mL) may be used satisfactorily as an irrigating solution in abscess cavities, the pleural space, the peritoneum and the cerebral ventricles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Aminoglycosides may impair neuromuscular transmission, and should not be given to patients with myasthenia gravis.
	Amikacin sulphate injection is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	A history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any aminoglycoside because of the known cross sensitivities of patients to drugs in this class.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Warnings</u></strong></p><p>Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity and nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established.</p><p>Neurotoxicity, manifested as vestibular and permanent bilateral auditory ototoxicity, can occur in patients with pre-existing renal damage and in patients with normal renal function treated at higher doses and/or for periods longer than those recommended. The risk of aminoglycoside-induced ototoxicity is greater in patients with renal damage. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness; skin tingling, muscle twitching and convulsions. The risk of hearing loss due to aminoglycosides increases with the degree of exposure to either high peak or high trough serum concentrations. Patients developing cochlear damage may not have symptoms during therapy to warn them of developing eighth-nerve toxicity, and total or partial irreversible bilateral deafness may occur after the drug has been discontinued. Aminoglycoside-induced ototoxicity is usually irreversible.</p><p>Aminoglycosides are potentially nephrotoxic.</p><p>The risk of nephrotoxicity is greater in patients with impaired renal function and in those who receive high doses or prolonged therapy.</p><p>Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides. The possibility of these phenomena should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate-anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.</p><p>Renal and eighth-nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Scrum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels and prolonged peak concentrations above 35 micrograms per mL. Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment.</p><p>Concurrent and/or sequential systemic, oral or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin,</p><p>viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.</p><p>The concurrent use of amikacin with potent diuretics (ethacrynic acid, or furosemide) should be avoided since diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.</p><p>&nbsp;</p><p>Caution should be applied to patients with pre-existing renal insufficiency, or pre-existing hearing or vestibular damage. Patients treated with parenteral aminoglycosides should be under close clinical observation because of the potential ototoxicity and nephrotoxicity associated with their use. Safety for treatment periods which are longer than 14 days has not been established. Precautions on dosage and adequate hydration should be observed.</p><p>In patients with impaired renal function or diminished glomerular filtration, renal function should be assessed by the usual methods prior to therapy and periodically during therapy. Daily doses should be reduced and/or the interval between doses lengthened in accordance with serum creatinine concentrations to avoid accumulation of abnormally high blood levels and to minimise the risk of ototoxicity. Regular monitoring of serum drug concentration and of renal function is particularly important in elderly patients, who may have reduced renal function that may not be evident in the results of routine screening tests i.e. blood urea and serum creatinine.</p><p>If therapy is expected to last seven days or more in patients with renal impairment, or 10 days in other patients, a pre-treatment audiogram should be obtained and repeated during therapy. Amikacin therapy should be stopped if tinnitus or subjective hearing loss develops, or if follow-up audiograms show significant loss of high frequency response.</p><p><strong><u>Neuro/Ototoxicity</u></strong></p><p>Neurotoxicity, manifested as vestibular and/or bilateral auditory ototoxicity, can occur in patients treated with aminoglycosides. The risk of aminoglycoside-induced ototoxicity is greater in patients with impaired renal function, and in those who receive high doses, or in those whose therapy is prolonged over 5-7 days. High frequency deafness usually occurs first and can be detected only by audiometric testing. Vertigo may occur and may be evidence of vestibular injury. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching and convulsions. The risk of ototoxicity due to aminoglycosides increases with the degree of exposure to either persistently high peak or high trough serum concentrations. Patients developing cochlear or vestibular damage may not have symptoms during therapy to warn them of developing eighth nerve toxicity, and total or partial irreversible bilateral deafness or disabling vertigo may occur after the drug has been discontinued. Aminoglycoside-induced ototoxicity is usually irreversible.</p><p>The use of amikacin in patients with a history of allergy to aminoglycosides or in patients who may have subclinical renal or eighth nerve damage induced by prior administration of nephrotoxic and/or ototoxic agents such as streptomycin, dihydrostreptomycin, gentamicin, tobramycin, kanamycin, bekanamycin, neomycin, polymyxin B, colistin, cephaloridine, or viomycin should be considered with caution, as toxicity may be additive.</p><p>In these patients amikacin should be used only if, in the opinion of the physician, therapeutic advantages outweigh the potential risks.</p><p><strong><u>Neuromuscular toxicity</u></strong></p><p>Neuromuscular blockade and respiratory paralysis have been reported following parenteral injection, topical instillation (as in orthopedic and abdominal irrigation or in local treatment of empyema), and following oral use of aminoglycosides. The possibility of respiratory paralysis should be considered if aminoglycosides are administered by any route, especially in patients receiving anesthetics, neuromuscular blocking agents (see section 4.5), or in patients receiving massive transfusions of citrate-anticoagulated blood. If neuromuscular blockade occurs, calcium salts may reverse respiratory paralysis, but mechanical respiratory assistance may be necessary. Neuromuscular blockade and muscular paralysis have been demonstrated in laboratory animals given high doses of amikacin.</p><p>Amikacin must not be used in patients with Myasthenia Gravis. Aminoglycosides should be used with caution in patients with muscular disorders such as parkinsonism, since these drugs may aggravate muscle weakness because of their potential curare-like effect on the neuromuscular junction.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Renal toxicity</u></strong></p><p>Aminoglycosides are potentially nephrotoxic. Renal toxicity is independent of plasma obtained at the peak (Cmax). The risk of nephrotoxicity is greater in patients with impaired renal function, and in those who receive high doses, or in those whose therapy is prolonged. Patients should be well hydrated during treatment and renal function should be assessed by the usual methods prior to starting therapy and daily during the course of treatment. A reduction of dosage is required if evidence of renal dysfunction occurs, such as presence of urinary casts, white or red cells, albuminuria, decreased creatinine clearance, decreased urine specific gravity, increased BUN, serum creatinine, or oliguria. If azotemia increases, or if a progressive decrease in urinary output occurs, treatment should be stopped.</p><p>Elderly patients may have reduced renal function which may not be evident in routine screening tests such as BUN or serum creatinine. A creatinine clearance determination may be more useful. Monitoring of renal function in elderly patients during treatment with aminoglycosides is particularly important.</p><p>Renal and eighth-cranial nerve function should be closely monitored especially in patients with known or suspected renal impairment at the onset of therapy, and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Serum concentrations of amikacin should be monitored when feasible to assure adequate levels and to avoid potentially toxic levels. Urine should be examined for decreased specific gravity, increased excretion of proteins, and the presence of cells or casts. Blood urea nitrogen, serum creatinine, or creatinine clearance should be measured periodically. Serial audiograms should be obtained where feasible in patients old enough to be tested, particularly high risk patients. Evidence of ototoxicity (dizziness, vertigo, tinnitus, roaring in the ears, and hearing loss) or nephrotoxicity requires discontinuation of the drug or dosage adjustment.</p><p>Concurrent and/or sequential systemic, oral, or topical use of other neurotoxic or nephrotoxic products, particularly bacitracin, cisplatin, amphotericin B, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides, should be avoided. Other factors that may increase risk of toxicity are advanced age and dehydration.</p><p>Inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function. Inactivation may continue in specimens of body fluids collected for assay, resulting in inaccurate aminoglycoside readings. Such specimens should be properly handled (assayed promptly, frozen, or treated with beta-lactamase).</p><p><strong><u>Allergic reactions</u></strong></p><p>Amikacin sulphate injection contains sodium metabisulfite, a sulphite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulphite sensitivity in the general population is uncommon and probably low. Sulphite sensitivity is seen more frequently in asthmatic than in non-asthmatic subjects.</p><p><strong><u>Other</u></strong></p><p>Aminoglycosides are quickly and almost totally absorbed when they are applied topically, except to the urinary bladder, in association with surgical procedures. Irreversible deafness, renal failure and death due to neuromuscular blockade have been reported following irrigation of both small and large surgical fields with an aminoglycoside preparation.</p><p>As with other antibiotics, the use of amikacin may result in overgrowth of nonsusceptible organisms. If this occurs, appropriate therapy should be instituted.</p><p>Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.</p><p>Macular infarction sometimes leading to permanent loss of vision has been reported following intravitreous administration (injection into the eye) of amikacin.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Paediatric use</u></strong></p><p>Aminoglycosides should be used with caution in premature and neonatal infants because of the renal immaturity of these patients and the resulting prolongation of serum half-life of these drugs.</p><p>The intraperitoneal use of amikacin is not recommended in young children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concurrent or serial use with other neurotoxic, ototoxic or nephrotoxic agents, particularly bacitracin, cisplatin, amphotericin B, cyclosporine, tacrolimus, cephaloridine, paromomycin, viomycin, polymyxin B, colistin, vancomycin, or other aminoglycosides should be avoided either systemically or topically because of the potential for additive effects.</p><p>Increased nephrotoxicity has been reported following concomitant parenteral administration of aminoglycoside antibiotics and cephalosporins. Concomitant cephalosporin use may spuriously elevate creatinine serum level determinations. Where this is not possible, monitor carefully. The risk of ototoxicity is increased when amikacin is used in conjunction with rapidly acting diuretic drugs, particularly when the diuretic is administered intravenously. Diuretics may enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Such agents include furosemide and ethacrynic acid which is itself an ototoxic agent. Irreversible deafness may result.</p><p>The use of amikacin is not recommended in patients under the influence of anaesthetics or muscle-relaxing drugs (including ether, halothane, d-tubocurarine, succinylcholine decamethonium, atracurium, rocuronium, vecuronium or in patients receiving massive transfusions of citrate-anticoagulated blood) as neuromuscular blockade and consequent respiratory depression may occur. If blockade occurs, calcium salts may reverse this phenomenon.</p><p>Indomethacin may increase the plasma concentration of amikacin in neonates.</p><p>In patients with severely impaired renal function, a reduction in activity of aminoglycosides may occur with concomitant use of penicillin-type drugs.</p><p><em>In vitro&nbsp;</em>admixture of aminoglycosides with beta-lactam antibiotics (penicillins or cephalosporins) may result in significant mutual inactivation. A reduction in serum activity may also occur when an aminoglycoside or penicillin-type drug is administered&nbsp;<em>in vivo&nbsp;</em>by separate routes. Inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function. Inactivation may continue in specimens of body fluids collected for assay, resulting in inaccurate aminoglycoside readings. Such specimens should be properly handled (assayed promptly, frozen, or treated with beta-lactamase).</p><p>There is an increased risk of hypocalcaemia when aminoglycosides are administered with bisphosphonates.</p><p>There is an increased risk of nephrotoxicity and possibly of ototoxicity when aminoglycosides are administered with platinum compounds.</p><p>Concomitantly administered thiamine (vitamin B1) may be destroyed by the reactive sodium metabisulfite component of the amikacin sulphate formulation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Fertility</u></strong></p><p>In reproduction toxicity studies in mice and rats, no effects on fertility or foetal toxicity were reported.</p><p><strong><u>Pregnancy</u></strong></p><p>Amikacin should be administered to pregnant women and neonatal infants only when clearly needed and under medical supervision (see section 4.4).</p><p>There are limited data on use of aminoglycosides in pregnancy. Aminoglycosides can cause foetal harm. Aminoglycosides cross the placenta and there have been reports of total, irreversible, bilateral congenital deafness in children whose mothers received streptomycin during pregnancy. Although adverse effects on the foetus or newborns have not been reported in pregnant women treated with other aminoglycosides, the potential for harm exists. If amikacin is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the foetus.</p><p><strong><u>Breast-feeding</u></strong></p><p>It is not known whether amikacin is excreted in human milk. A decision should be made whether to discontinue breast-feeding or to discontinue therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Due to the occurrence of some adverse reactions (see section 4.8) the ability to drive and use machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common (&ge;1/10), common (&ge;1/100, &lt; 1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000), very rare (&lt; 1/10000), and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Term</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Superinfections or colonisation with resistant bacteria or yeast<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaemia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaphylactic response (anaphylactic reaction, anaphylactic shock and anaphylactoid reaction), hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypomagnesaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Paralysis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tremor<sup>a</sup>, paresthesia<sup>a</sup>, headache, balance disorder<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Blindness<sup>b</sup>, retinal infarction<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tinnitus<sup>a</sup>, hypoacusis<sup>a</sup></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Deafness<sup>a</sup>, deafness neurosensory<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Apnoea, bronchospasm</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pruritus, urticaria</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal, connective tissue and bone disorders</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Arthralgia, muscle twitching<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure acute, nephropathy toxic, cells in urine<sup>a</sup></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Oliguria<sup>a</sup>, blood creatinine increased<sup>a</sup>, albuminuria<sup>a</sup>, azotemia<sup>a</sup>, red blood cells urine<sup>a</sup>, white blood cells urine<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pyrexia</p></td></tr></tbody></table><p><sup>a&nbsp;</sup>See section 4.4.</p><p><sup>b</sup>&nbsp;Amikacin is not formulated for intavitreal use. Blindness and retinal infarction have been reported following intravitreous administrations (injection into the eye) of amikacin.</p><p>All aminoglycosides have the potential to induce ototoxicity, renal toxicity, and neuromuscular blockade. These toxicities occur more frequently in patients with renal impairment, in patients treated with other ototoxic or nephrotoxic drugs, and in patients treated for longer periods and/or with higher doses than recommended (see section 4.4).</p><p>Renal function changes are usually reversible when the drug is discontinued.</p><p>Toxic effects on the eighth cranial nerve can result in hearing loss, loss of balance, or both. Amikacin primarily affects auditory function. Cochlear damage includes high frequency deafness and usually occurs before clinical hearing loss can be detected by audiometric testing (see section 4.4).</p><p><strong><u>To report side effects:</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2340</p><p><strong>Reporting Hotline:</strong> 19999</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc<strong>.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of overdosage there is a general risk for nephro-, oto- and neurotoxic (neuromuscular blockage) reactions. Neuromuscular blockage with respiratory arrest needs appropriate treatment including application of ionic calcium (e.g. as gluconate or lactobionat in 10-20% solution) (see section 4.4). In the event of overdosage or toxic reaction, peritoneal dialysis or haemodialysis will aid in the removal of amikacin from the blood.</p><p>Amikacin levels are also reduced during continuous arteriovenous hemofiltration. In the newborn infant, exchange transfusion may also be considered.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Anti-infectives for systemic use, ATC code: J01GB06</p><p>Amikacin sulphate is an aminoglycoside antibiotic which is active against a broad spectrum of Gram-negative organisms, including&nbsp;<em>Pseudomonas</em>&nbsp;spp,&nbsp;<em>Escherichia coli</em>, indole-positive and indole-negative&nbsp;<em>Proteus</em>&nbsp;spp,&nbsp;<em>Klebsiella-Enterobacter-Serratia</em>&nbsp;spp,&nbsp;<em>Salmonella, Shigella, Minea-Herellae</em>,&nbsp;<em>Citrobacter Freundii</em>&nbsp;and&nbsp;<em>Providencia</em>&nbsp;spp.</p><p>Many strains of these Gram-negative organisms resistant to gentamicin and tobramycin may show sensitivity to amikacin&nbsp;<em>in vitro</em>. The principal Gram-positive organism sensitive to amikacin is&nbsp;<em>Staphylococcus aureus</em>, including methicillin-resistant strains. Amikacin has some activity against other Gram-positive organisms including certain strains of&nbsp;<em>Streptococcus</em>&nbsp;<em>pyogenes</em>, Enterococci and&nbsp;<em>Diplococcus pneumoniae</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amikacin is rapidly absorbed after intramuscular injection. Peak serum levels of approximately 11 mg/L and 23 mg/L are reached one hour after intramuscular doses of 250 mg and 500 mg respectively. Levels 10 hours after injection are of the order of 0.3 mg/L and 2.1 mg/L respectively.</p><p>Twenty per cent or less is bound to serum protein and serum concentrations remain in the bactericidal range for sensitive organisms for 10 to 12 hours.</p><p>Amikacin diffuses readily through extracellular fluids and is excreted in the urine unchanged, primarily by glomerular filtration. Half-life in individuals with normal renal functions is two to three hours.</p><p>Following intramuscular administration of a 250 mg dose, about 65% is excreted in six hours and 91% within 24 hours. The urinary concentrations average 563 mg/L in the first 6 hours and 163 mg/L over 6 to 12 hours. Mean urine concentrations after a 500 mg intramuscular dose average 832 mg/L in the first six hours.</p><p>Single doses of 500 mg administered to normal adults as an intravenous infusion over a period of 30 minutes produce a mean peak serum concentration of 38 mg/L at the end of the infusion. Repeated infusions do not produce drug accumulation.</p><p>Amikacin has been found in cerebrospinal fluid, pleural fluid, amniotic fluid and in the peritoneal cavity following parenteral administration.</p><p>Data from multiple daily dose trials show that spinal fluid levels in normal infants are approximately 10 to 20% of the serum concentrations and may reach 50% in meningitis.</p><p><strong>Intramuscular and intravenous administration</strong></p><p>In neonates and particularly in premature babies, the renal elimination of amikacin is reduced.</p><p>In a single study in newborns (1-6 days of post natal age) grouped according to birth weights (&lt;2000, 2000-3000 and &gt;3000 g). Amikacin was administered intramuscularly and/or intravenously at a dose of 7.5 mg/kg. Clearance in neonates &gt;3000 g was 0.84 mL/min/kg and terminal half-life was about 7 hours. In this group, the initial volume of distribution and volume of distribution at steady state was 0.3 mL/kg and 0.5 mg/kg, respectively. In the groups with lower birth weight clearance/kg was lower and half-life longer. Repeated dosing every 12 hours in all the above groups did not demonstrate accumulation after 5 days.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No further relevant information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium metabisulphite</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium citrate dihydrate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sodium hydroxide pellets</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Sulphuric acid reagent grade</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Nitrogen gas</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Water for injection</li></ol></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amikacin is incompatible with some penicillins and cephalosporins, amphotericin, chlorothiazide sodium, erythromycin gluceptate, heparin, nitrofurantoin sodium, phenytoin sodium, thiopentone sodium and warfarin sodium, and depending on the composition and strength of the vehicle, tetracyclines, vitamins of the B group with vitamin C, and potassium chloride.</p><p>At times, amikacin may be indicated as concurrent therapy with other antibacterial agents in mixed or superinfections. In such instances, amikacin should not be physically mixed with other antibacterial agents in syringes, infusion bottles or any other equipment. Each agent should be administered separately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacture.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; 2mL in glass ampoule, Type I, USP with printed label, 5 ampules in an ampoule tray, packed in a printed carton along with a leaflet.</p><p>&sect; 2mL in glass ampoule, Type I, USP with printed label, 50 ampules in an ampoule tray, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only, discard any unused solution.</p><p>Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever the solution and container permit.</p><p>After dilution by using the following diluents:</p><p>&sect; 5% Dextrose</p><p>&sect; 0.9% NaCl</p><p>&sect; Sodium lactate solution</p><p>Diluted solutions retain their physical and chemical stability for 24 hours at room temperature.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Road,
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21. September. 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>